Cardinal Health Stock News

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.

Even though some early first-quarter earnings have come in very solid, the reality is the market is teetering and could be ready to plunge.

DUBLIN, Ohio , April 1, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2022 on May 5 prior to the opening of trading on the New Y

Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.

Despite the COVID-19 pandemic-induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain

Cardinal Health Remains A Bargain

Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.

Dividend aristocrats are a particularly intriguing area of the market to consider, as investors can rely on these companies for consistent increases in payouts over the years.

Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.

Johnson & Johnson (JNJ) and three leading drug distributors in the U.S., Cardinal Health (CAH), McKesson Corporation (MCK), and AmerisourceBergen (ABC), continue to draw the ire…

The U.S. Justice and Treasury Departments should review the tax deductions four drugmakers made related to their $26 billion opioid settlement, the U.S. House Oversight and Reform Committee said in a

The "Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com''s offering. Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area. The model discusses in detail the impact of COVID-19 on Carotid and Renal Artery Stents market for the year 2020 and beyond. Three types of therapies are recommended for carotid stenosis. These therapies include medication, endovascular intervention, and endarterectomy. Endarterectomy is recommended over stenting to patients who are suffering from stenosis (>70%) and have had symptoms for the last six months to a year. It is not recommended to individuals with 50% or less stenosis in the carotid artery. Endovascular therapy is … Full story available on Benzinga.com

NEW YORK (AP) — Releasing years of anguish and anger, victims of opioid abuse and those who have lost loved ones to an addiction crisis stretching back more than two decades unloaded their emotions on members of the family they blame for fueling the deadly epidemic. Thursday’s unusual hearing, conducted virtually in U.S. Bankruptcy Court, gave them what they have wanted for years: the chance to confront members of the Sackler family who own OxyContin maker Purdue Pharma and tell them about the lasting pain that addiction and overdoses have had in their lives. “When you created OxyContin, you created so much loss for so many people. … I’m outraged that you haven’t owned up to the crisis that you’ve created," said Kay Scarpone, addressing the three Sackler family members in attendance. She lost her son Joseph Scarpone, a former marine, to addiction a month before his 26th birthday. Appearing only via audio was Richard Sackler, the former Purdue president and board chair who has said the company and family bear no responsibility for the opioid crisis, and also a son of Raymond Sackler, one of the three brothers who in the 1950s bought the company that became Purdue Pharma.

If history is any guide, there may be good fortune ahead for shares of Cardinal Health (NYSE: CAH ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses … Full story available on Benzinga.com